Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Folia Histochemica et Cytobiologica
MENU
Shortcuts Submit an article Author Guidelines Ahead of Print Reviewers 2023 Editorial Board

open access

Vol 49, No 2 (2011)
Original paper
Submitted: 2011-12-19
Published online: 2011-07-11
View PDF Download PDF file
Get Citation

JAK2 mutation status, hemostatic risk factors and thrombophilic factors in essential thrombocythemia (ET) patients

Bożena Sokołowska, Aleksandra Nowaczyńska, Ksenia Bykowska, Sylwia Chocholska, Katarzyna Wejksza, Adam Walter-Croneck, Tomasz Gromek, Anna M. Kowalska, Martyna Kandefer-Szerszeń, Anna Dmoszyńska
DOI: 10.5603/FHC.2011.0037
·
Folia Histochem Cytobiol 2011;49(2):267-271.

open access

Vol 49, No 2 (2011)
ORIGINAL PAPERS
Submitted: 2011-12-19
Published online: 2011-07-11

Abstract

The recently discovered JAK2 V617F point mutation, found in 50–60% of ET patients, has been reported to be associated with a higher risk of thrombotic events. In this study, we explored if JAK2 V617F mutation, or coexisting thrombophilic and hemostatic risk factors, contributed to these complications. We examined 32 patients with ET, and looked for pathogenetic JAK2 V617F mutation and prothrombotic genes mutations: factor V Leiden, prothrombin and MTHFR. We also evaluated plasma levels of fibrinogen, factors VIII and XII, AT, protein C, protein S and serum level of homocysteine. Urokinase concentration was assessed in patients’ plasma as well as platelet lysates. There was no difference in the number of thrombotic complications between ET patients with and without JAK2 mutation. However, we found a number of thrombophilic and hemostatic risk factors that could contribute to thrombotic complications in ET patients. (Folia Histochemica et Cytobiologica 2011; Vol. 49, No. 2, pp. 267–271)

Abstract

The recently discovered JAK2 V617F point mutation, found in 50–60% of ET patients, has been reported to be associated with a higher risk of thrombotic events. In this study, we explored if JAK2 V617F mutation, or coexisting thrombophilic and hemostatic risk factors, contributed to these complications. We examined 32 patients with ET, and looked for pathogenetic JAK2 V617F mutation and prothrombotic genes mutations: factor V Leiden, prothrombin and MTHFR. We also evaluated plasma levels of fibrinogen, factors VIII and XII, AT, protein C, protein S and serum level of homocysteine. Urokinase concentration was assessed in patients’ plasma as well as platelet lysates. There was no difference in the number of thrombotic complications between ET patients with and without JAK2 mutation. However, we found a number of thrombophilic and hemostatic risk factors that could contribute to thrombotic complications in ET patients. (Folia Histochemica et Cytobiologica 2011; Vol. 49, No. 2, pp. 267–271)

Full Text:

View PDF Download PDF file
Get Citation

Keywords

JAK2 mutation; ET; thrombophilic factors

About this article
Title

JAK2 mutation status, hemostatic risk factors and thrombophilic factors in essential thrombocythemia (ET) patients

Journal

Folia Histochemica et Cytobiologica

Issue

Vol 49, No 2 (2011)

Article type

Original paper

Pages

267-271

Published online

2011-07-11

Page views

2349

Article views/downloads

2101

DOI

10.5603/FHC.2011.0037

Bibliographic record

Folia Histochem Cytobiol 2011;49(2):267-271.

Keywords

JAK2 mutation
ET
thrombophilic factors

Authors

Bożena Sokołowska
Aleksandra Nowaczyńska
Ksenia Bykowska
Sylwia Chocholska
Katarzyna Wejksza
Adam Walter-Croneck
Tomasz Gromek
Anna M. Kowalska
Martyna Kandefer-Szerszeń
Anna Dmoszyńska

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl